Tazeen Ahmad
Stock Analyst at B of A Securities
(3.33)
# 985
Out of 5,161 analysts
219
Total ratings
47.8%
Success rate
2.07%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Buy | $97 → $93 | $63.36 | +46.78% | 20 | Feb 20, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $246 → $260 | $229.01 | +13.53% | 12 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $462 | $317.23 | +45.64% | 7 | Jan 30, 2026 | |
| BLTE Belite Bio | Initiates: Buy | $195 | $169.55 | +15.01% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $18.39 | +52.26% | 10 | Jan 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $746.61 | +15.19% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $21.71 | +167.16% | 7 | Jan 2, 2026 | |
| FULC Fulcrum Therapeutics | Maintains: Underperform | $6 → $7 | $7.63 | -8.26% | 7 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $71 → $112 | $77.50 | +44.52% | 1 | Dec 9, 2025 | |
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $26.38 | +13.72% | 5 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $53 | $41.80 | +26.79% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $104 | $92.03 | +13.01% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $708.85 | +25.13% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $17.04 | -6.10% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $27 | $21.27 | +26.94% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $90.10 | +48.72% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.61 | +73.54% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $91.15 | +4.22% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.38 | +79.00% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $9.31 | -57.04% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $24.45 | -67.28% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $20.70 | +30.43% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $12.48 | +124.36% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $8.45 | +373.37% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $127.78 | +40.08% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $17.38 | +26.58% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $6.15 | -51.22% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.37 | +4.38% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.44 | +83.82% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.17 | +412.82% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.87 | +69.11% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.35 | -54.02% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $3.37 | +78.04% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $25.90 | -42.08% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $303.37 | -80.22% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.53 | +945.75% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $157.46 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $20.06 | +1,395.51% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.59 | +247.49% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $23.53 | +103.99% | 6 | Oct 10, 2018 |
PTC Therapeutics
Feb 20, 2026
Maintains: Buy
Price Target: $97 → $93
Current: $63.36
Upside: +46.78%
Ascendis Pharma
Jan 30, 2026
Maintains: Buy
Price Target: $246 → $260
Current: $229.01
Upside: +13.53%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Buy
Price Target: $529 → $462
Current: $317.23
Upside: +45.64%
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $169.55
Upside: +15.01%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $18.39
Upside: +52.26%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $746.61
Upside: +15.19%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $21.71
Upside: +167.16%
Fulcrum Therapeutics
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $7.63
Upside: -8.26%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $77.50
Upside: +44.52%
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $26.38
Upside: +13.72%
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $41.80
Upside: +26.79%
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $92.03
Upside: +13.01%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $708.85
Upside: +25.13%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $17.04
Upside: -6.10%
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $21.27
Upside: +26.94%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $90.10
Upside: +48.72%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $4.61
Upside: +73.54%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $91.15
Upside: +4.22%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.38
Upside: +79.00%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $9.31
Upside: -57.04%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $24.45
Upside: -67.28%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $20.70
Upside: +30.43%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $12.48
Upside: +124.36%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $8.45
Upside: +373.37%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $127.78
Upside: +40.08%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $17.38
Upside: +26.58%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $6.15
Upside: -51.22%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.37
Upside: +4.38%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.44
Upside: +83.82%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.17
Upside: +412.82%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $8.87
Upside: +69.11%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.35
Upside: -54.02%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $3.37
Upside: +78.04%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $25.90
Upside: -42.08%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $303.37
Upside: -80.22%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.53
Upside: +945.75%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $157.46
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $20.06
Upside: +1,395.51%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.59
Upside: +247.49%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $23.53
Upside: +103.99%